文献速递胸部肿瘤

奥希替尼联合贝伐珠单抗对比奥希替尼单药治疗既往EGFR-TKI治疗后EGFR T790M突变非小细胞肺癌的疗效:WJOG 8715L II期随机临床试验

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

该II期随机试验纳入87例既往EGFR-TKI治疗后进展且伴EGFR T790M突变的晚期肺腺癌患者,随机接受奥希替尼联合贝伐珠单抗或奥希替尼单药治疗。联合组客观缓解率高于单药组(68% vs 54%),但中位无进展生存期未延长(9.4个月 vs 13.5个月;校正风险比1.44;80%CI 1.00-2.08;

要点

  • 奥希替尼联合贝伐珠单抗未延长T790M突变肺癌患者的中位无进展生存期。
  • 联合组客观缓解率68%,单药组54%,但差异未达统计学意义。
  • 联合组3级及以上不良事件以蛋白尿(23%)和高血压(20%)常见。

核心结论

  • 在既往EGFR-TKI治疗后进展且伴EGFR T790M突变的晚期肺腺癌患者中,奥希替尼联合贝伐珠单抗未能延长无进展生存期。

研究设计与样本

  • 本研究为II期随机临床试验,包含6例导入期患者和81例随机分组患者(意向治疗人群共87例),按1:1随机分配至联合组或单药组。

主要发现

  • 联合组3级及以上常见不良事件为蛋白尿(9例,23%)和高血压(8例,20%)。

临床怎么用

  • 对于既往EGFR-TKI治疗后进展且伴EGFR T790M突变的晚期肺腺癌,奥希替尼联合贝伐珠单抗未显示无进展生存获益,不支持常规联合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although treatment with first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies in patients with EGFR-mutated lung adenocarcinoma, recent single-arm studies have suggested that osimertinib plus antiangiogenic inhibitor might not work synergistically. OBJECTIVE: To explore the efficacy and safety of osimertinib plus bevacizumab compared with osimertinib alone in patients with lung adenocarcinoma with EGFR T790M mutation. DESIGN, SETTING, AND PARTICIPANTS: Patients with advanced lung adenocarcinoma that progressed with prior EGFR-TKI treatment (other than third-generation TKI) and acquired EGFR T790M mutation were enrolled. This study comprises a lead-in part with 6 patients and a subsequent phase 2 part. In phase 2, patients were randomized to osimertinib plus bevacizumab or osimertinib alone in a 1:1 ratio. INTERVENTIONS: The combination arm received oral osimertinib (80 mg, every day) plus intravenous bevacizumab (15 mg/kg, every 3 weeks) until progression or unacceptable toxic effects. The control arm received osimertinib monotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) assessed by investigators. Secondary end points consisted of overall response rate, time to treatment failure, overall survival, and safety. RESULTS: From August 2017 through September 2018, a total of 87 patients were registered (6 in the lead-in part and 81 in the phase 2 part [intention-to-treat population]). Among those randomized, the median (range) age was 68 (41-82) years; 33 (41%) were male; 37 (46%) had an Eastern Cooperative Oncology Group performance status of 0; and 21 (26%) had brain metastasis. Although the overall response rate was better with osimertinib plus bevacizumab than osimertinib alone (68% vs 54%), median PFS was not longer with osimertinib plus bevacizumab (9.4 months vs 13.5 months; adjusted hazard ratio, 1.44; 80% CI, 1.00 to 2.08; P = .20). Median time to treatment failure was also shorter in the combination arm vs the osimertinib arm (8.4 months vs 11.2 months; P = .12). Median overall survival was not different in the combination arm vs osimertinib arm (not reached vs 22.1 months; P = .96). In the combination arm, common adverse events of grade 3 or higher were proteinuria (n = 9; 23%), hypertension (n = 8; 20%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial comparing osimertinib plus bevacizumab vs osimertinib alone, the combination arm failed to show prolongation of PFS in patients with advanced lung adenocarcinoma with EGFR T790M mutation. TRIAL REGISTRATION: UMIN Clinical Trials Registry Identifier: UMIN000023761.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Akamatsu H, Toi Y, Hayashi H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33410885. doi:10.1001/jamaoncol.2020.6758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。